Results & investor presentations

DSM provides Q1 2023 trading update

Prioritising profitability over sales volumes has supported our margins, which improved sequentially into the first quarter.”

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, DSM and DSM-Firmenich are required to announce transactions in relation to the ordinary shares in their respective share capital in accordance with the Dutch public offer rules.

DSM agrees terms to acquire postbiotics pioneer Adare Biome

DSM announces that it has entered into exclusive negotiations with Adare Pharma Solutions in order to acquire Adare Biome, a pioneer in the development and manufacturing of postbiotics, for an enterprise value of €275 million. This transaction represents an estimated 2023 EV/EBITDA multiple of 18x.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM completes sale of Engineering Materials business

Royal DSM announces the completion of the sale of its Engineering Materials business to Advent International and LANXESS for an Enterprise Value of €3.85 billion.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM quantifies food system impact

DSM reveals the first audited results of its progress in helping to address urgent societal and environmental challenges linked to how the world produces and consumes food.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM publishes Integrated Annual Report 2022

Royal DSM, a global purpose-led, performance-driven leader in Health, Nutrition & Bioscience, today announces the publication of its 2022 Integrated Annual Report (IAR).

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM reports 2022 results

DSM delivered a solid performance in 2022 against a background of continued global supply chain challenges and significantly higher energy and raw materials costs, consolidating the strong growth of 2021. Pricing actions to counter higher costs, supported top-line growth, however with a price-cost gap impacting near-term margins, especially in Animal, Nutrition & Health.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

DSM - delivery of shares

Following the Offering Circular published on 22 November 2022, Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.

Cargill and Royal DSM to establish joint venture to bring zero-calorie, cost-effective sweeteners to market faster

Companies to produce highly sought-after molecules such as steviol glycosides Reb M and Reb D through fermentation.

DSM informs market on the completion of the sale of Fibrant’s caprolactam business to Highsun

DSM anticipates receiving about €200 million in cash in various steps in 2018 and 2019.

DSM finalizes repurchase of shares to cover existing option plans and stock dividends

DSM repurchased 209,327 shares from 1 to 5 October 2018 at an average price of €90.13, finalizing program to repurchase 1,100,000 shares for a total of €98.9 million.

DSM - repurchase of shares (24-28 September 2018)

DSM repurchased 121,592 shares from 24 to 28 September 2018 at an average price of €91.88.

DSM - repurchase of shares (17-21 September 2018)

DSM repurchased 69,638 shares from 17 to 21 September 2018 at an average price of €91.24.

DSM - repurchase of shares (10-14 September 2018)

DSM repurchased 94,032 shares from 10 to 14 September 2018 at an average price of €88.38.

DSM tops Dow Jones Sustainability World Index

DSM recognized among the DJSI leaders for 15 years running and held the number one position in the sector eight times.

DSM - repurchase of shares (3-7 September 2018)

DSM repurchased 189,309 shares from 3 to 7 September 2018 at an average price of €88.16.

DSM - repurchase of shares (27-31 August 2018)

DSM repurchased 117,471 shares from 27 to 31 August 2018 at an average price of €91.17.

DSM - repurchase of shares (20-24 August 2018)

DSM repurchased 82,975 shares from 20 to 24 August 2018 at an average price of €89.58.

DSM - repurchase of shares (13-17 August 2018)

DSM repurchased 215,656 shares from 13 to 17 August 2018 at an average price of €89.80.

DSM announces repurchase of shares to cover share-based compensation plans and stock dividend

DSM intends to repurchase 1,100,000 ordinary shares: 500,000 to cover commitments under share-based compensation plans and 600,000 to cover part of the interim dividend 2018.

DSM becomes largest shareholder in Mixfit Inc. to enter B2C personalized nutrition

Acquisition builds on partnership combining DSM’s unparalleled expertise in micronutrients with Mixfit technology.

DSM informs market on the announced sale of DSM Sinochem Pharmaceuticals to Bain Capital

Bain Capital intends to acquire DSM Sinochem Pharmaceuticals, a DSM and Sinochem Group 50/50 joint venture, with the transaction expected to be completed in the fourth quarter of 2018 subject to customary regulatory approvals and consultations.

DSM finalizes repurchase of shares to cover existing option plans and stock dividends

DSM repurchased 324,894 shares from 15 to 20 June 2018 at an average price of €88.18, concluding program to repurchase 1,600,000 shares for a total of €136.7 million.

DSM strategy update

With its unique science-based competences, DSM is ideally positioned to capture the growth opportunities offered by the global megatrends and Sustainable Development Goals (SDGs), with a particular focus on Nutrition & Health, Climate & Energy and Resources & Circularity.

DSM - repurchase of shares (8-14 June 2018)

DSM repurchased 132,098 shares from 8 to 14 June 2018 at an average price of €89.07.

DSM - repurchase of shares (1-7 June 2018)

DSM repurchased 141,033 shares from 1 to 7 June 2018 at an average price of €88.22.

DSM - repurchase of shares (25-31 May 2018)

DSM repurchased 233,975 shares from 25 to 31 May 2018 at an average price of €86.30.

DSM - repurchase of shares (18-24 May 2018)

DSM repurchased 176,500 shares from 18 to 24 May 2018 at an average price of €88.02.

DSM informs market on the announced sale of Fibrant’s Caprolactam business to Highsun

DSM and CVC Capital Partners indirectly own 35% and 65% respectively of the shares of Fibrant BV through Chemicalnvest joint venture.

DSM - repurchase of shares (14-17 May 2018)

DSM repurchased 91,500 shares from 14 to 17 May 2018 at an average price of €87.39.

Final dividend 2017 Royal DSM

DSM declares a dividend for the financial year 2017 of €1.85 per ordinary share.

DSM announces results of 2018 Annual General Meeting of Shareholders

DSM held its Annual General Meeting of Shareholders on 9 May 2018. Shareholders approved all resolutions on the agenda.

DSM reports Q1 2018 results

Royal DSM issues its full Q1 2018 results, which are in line with the preliminary figures for Q1 2018 previously announced on 12 April 2018.

DSM - repurchase of shares (6-12 April 2018)

DSM repurchased 88,350 shares from 6 to 12 April 2018 at an average price of €81.74.

DSM announces preliminary Q1 2018 results and increases outlook

Continued strong organic sales growth in underlying business estimated at 11%. Adjusted EBITDA growth of underlying business estimated at 7% despite significant FX headwind. Additional temporary vitamin price benefit estimated at €165m on Adjusted EBITDA. Overall very strong quarter with total Adjusted EBITDA up 55%.

DSM - repurchase of shares (3-5 April 2018)

DSM repurchased 87,000 shares from 3 to 5 April 2018 at an average price of €80.10.

DSM - repurchase of shares (23-29 March 2018)

DSM repurchased 188,000 shares from 23 to 29 March 2018 at an average price of €79.38.

DSM - repurchase of shares (19-22 March 2018)

DSM repurchased 136,650 shares from 19 to 22 March 2018 at an average price of €80.59.

DSM announces repurchase of shares to cover share based compensation plans and stock dividend

DSM intends to repurchase 1,600,000 ordinary shares to cover commitments under share based compensation plans and and part of the final dividend 2017.

DSM publishes 2017 Integrated Annual Report

The 2017 Integrated Annual Report details the company's progress and performance over the year in terms of People, Planet and Profit.

DSM reports 2017 results

DSM again reports an excellent year, as it significantly exceeded its Strategy 2018 targets for EBITDA, ROCE and organic sales growth.

DSM and Amyris close transactions for Brazilian production facility

Sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’s high-volume products finalized.

DSM acquires BioCare Copenhagen to expand gut health ingredients portfolio with probiotics

DSM expands its offering in gut health ingredients with probiotics, an attractive market segment in nutritional ingredients, growing an estimated 7% per year.

DSM expands strategic alliance with Amyris and acquires Brazilian production facility from Amyris

DSM and Amyris enhance their strategic alliance through the sale of Amyris Brasil Ltda to DSM and the establishment of a long-term manufacturing partnership for Amyris’ high-volume products.

DSM finalizes repurchase of shares to cover existing option plans and stock dividends

DSM repurchased 151,900 shares from 10 to 14 November 2017 at an average price of €75.63, concluding program to repurchase 1,600,000 shares for a total of €109.3 million.

DSM - repurchase of shares (3-9 November 2017)

DSM repurchased 243,624 shares from 3 to 9 November 2017 at an average price of €76.15.

DSM reports results first nine months 2017

Strong performance in Q3 2017, contributing to very good first nine months.

DSM - repurchase of shares (6-12 October 2017)

DSM repurchased 37,600 shares from 6 to 12 October 2017 at an average price of €69.54.

DSM - repurchase of shares (29 September - 5 October 2017)

DSM repurchased 140,692 shares from 29 September to 5 October 2017 at an average price of €69.52.

DSM - repurchase of shares (22-28 September 2017)

DSM repurchased 163,310 shares from 22 to 28 September 2017 at an average price of €67.75.

DSM updates market on Strategy 2018

EBITDA and ROCE outlook for 2017 confirmed. DSM aims to continue to deliver against its strategic targets in 2018. DSM brings forward its regular strategic review process for the period beyond 2018 and expects to share the conclusions before the summer of 2018.

DSM - repurchase of shares (15-21 September 2017)

DSM repurchased 117,424 shares from 15 to 21 September 2017 at an average price of €66.56.

DSM to acquire Twilmij B.V. to strengthen position in Animal Nutrition & Health

Twilmij’s core values, customer portfolio and solutions are a perfect fit with DSM’s ambitions in the animal nutrition & health market.

DSM - repurchase of shares (8-14 September 2017)

DSM repurchased 128,851 shares from 8 to 14 September 2017 at an average price of €66.04.

DSM - repurchase of shares (1-7 September 2017)

DSM repurchased 142,315 shares from 1 to 7 September 2017 at an average price of €65.01.

DSM among leaders in Dow Jones Sustainability World Index

DSM again named among worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index having been named among the global leaders for the past 14 years and holding the number one position in the sector seven times, including last year.

DSM - repurchase of shares (25-31 August 2017)

DSM repurchased 188,430 shares from 25 to 31 August 2017 at an average price of €64.01.

DSM informs market on Patheon N.V.

Thermo Fisher Scientific Inc. has completed the acquisition of Patheon N.V. (NYSE:PTHN), a company in which DSM held approximately 48.7 million ordinary shares.

DSM - repurchase of shares (18-24 August 2017)

DSM repurchased 185,837 shares from 18 to 24 August 2017 at an average price of €63.98.

DSM - repurchase of shares (14-17 August 2017)

DSM repurchased 100,017 shares from 14 to 17 August 2017 at an average price of €63.21.

DSM announces repurchase of shares to cover existing option plans and stock dividend

DSM intends to repurchase 1,600,000 ordinary shares to cover commitments under management and personnel option plans and for part of the interim dividend 2017.

DSM reports H1 2017 results

DSM maintained its positive momentum with a very strong first half-year performance with Q2 another very good quarter.

DSM appoints new EVP People & Organization and member of the Executive Committee

Judith Wiese will join DSM as Executive Vice President Group People & Organization on 1 October 2017.

DSM finalizes repurchase of shares to cover existing option plans and stock dividends

DSM repurchased 261,898 shares from 7 to 13 July 2017 at an average price of €63.24, concluding program to repurchase 2,900,000 shares for a total of €187.2 million.

DSM - repurchase of shares (30 June - 6 July 2017)

DSM repurchased 218,403 shares from 30 June to 6 July 2017 at an average price of €63.72.

DSM - repurchase of shares (23-29 June 2017)

DSM repurchased 182,175 shares from 23 to 29 June 2017 at an average price of €65.07.

DSM - repurchase of shares (16-22 June 2017)

DSM repurchased 122,307 shares from 16 to 22 June 2017 at an average price of €67.16.

DSM - repurchase of shares (9-15 June 2017)

DSM repurchased 123,435 shares from 9 to 15 June 2017 at an average price of €66.00.

DSM - repurchase of shares (2-8 June 2017)

DSM repurchased 132,717 shares from 2 to 8 June 2017 at an average price of €65.73.

DSM - repurchase of shares (26 May - 1 June 2017)

DSM repurchased 123,673 shares from 26 May to 1 June 2017 at an average price of €66.16.

DSM - repurchase of shares (19-25 May 2017)

DSM repurchased 123,847 shares from 19 to 25 May 2017 at an average price of €66.10.

DSM - repurchase of shares (12-18 May 2017)

DSM repurchased 139,447 shares from 12 to 18 May 2017 at an average price of €66.66.

DSM informs market on Patheon N.V.

Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per ordinary share in cash.

DSM - repurchase of shares (5-11 May 2017)

DSM repurchased 128,958 shares from 5 to 11 May 2017 at an average price of €65.76.

Royal DSM to make equity investment in Amyris with the purpose of establishing a long-term relationship

DSM to make equity investment in Amyris and the companies to enter development cooperation focused on products for the health and nutrition markets.

DSM - repurchase of shares (28 April - 4 May 2017)

DSM repurchased 114,048 shares from 28 April to 4 May 2017 at an average price of €66.44.

Final dividend 2016 Royal DSM

DSM declares a dividend for the financial year 2016 of €1.75 per ordinary share.

DSM announces results of 2017 Annual General Meeting of Shareholders

DSM held its Annual General Meeting of Shareholders on 3 May 2017. Shareholders approved all resolutions on the agenda.

DSM reports Q1 2017 results

DSM reports a very strong first quarter in 2017.

DSM - repurchase of shares (21-27 April 2017)

DSM repurchased 126,540 shares from 21 to 27 April 2017 at an average price of €65.81.

DSM - repurchase of shares (18-20 April 2017)

DSM repurchased 75,948 shares from 18 to 20 April 2017 at an average price of €65.02.

DSM - repurchase of shares (7-13 April 2017)

DSM repurchased 126,073 shares from 7 to 13 April 2017 at an average price of €65.16.

DSM - repurchase of shares (31 March - 6 April 2017)

DSM repurchased 134,338 shares from 31 March to 6 April 2017 at an average price of €64.04.

DSM - repurchase of shares (24-30 March 2017)

DSM repurchased 235,605 shares from 24 to 30 March 2017 at an average price of €62.81.

DSM - repurchase of shares (17-23 March 2017)

DSM repurchased 308,025 shares from 17 to 23 March 2017 at an average price of €62.12.

DSM proposes Managing Board re-appointment and two new Supervisory Board members

DSM proposes re-appointment of Dimitri de Vreeze the Managing Board and appointment of John Ramsay and Frits van Paasschen to the Supervisory Board.

DSM - repurchase of shares (13-16 March 2017)

DSM repurchased 222,563 shares from 13 to 16 March 2017 at an average price of €62.92 for a total of €14.0 million.

DSM announces repurchase of shares to cover existing option plans and stock dividend

DSM to repurchase 2,900,000 ordinary shares to cover commitments under management and personnel option plans and for part of final dividend 2016.

DSM publishes 2016 Integrated Annual Report

2016 Integrated Annual Report, in which DSM reports on its progress and performance over the year in terms of People, Planet and Profit, published on 3 March 2017.

DSM reports 2016 results

DSM reports a very good 2016 in which it achieved strong EBITDA and ROCE growth, well ahead of the mid-term targets set out in its Strategy 2018: Driving Profitable Growth.

DSM new presentation of accounts as from Q4 2016

DSM updates way its financial results are presented starting with Q4/full-year results for 2016, following recent changes to accounting and reporting guidelines in Europe.

DSM finalizes repurchase of shares to cover existing option plans

DSM repurchased 361,907 shares from 2 to 8 December 2016 at an average price of €56.21 and concluded the program to repurchase 1,700,000 shares.

DSM - repurchase of shares (25 November 2016 - 1 December 2016)

DSM repurchased 215,424 of its own shares from 25 November to 1 December 2016 at an average price of €57.32.

DSM - repurchase of shares (18-24 November 2016)

DSM repurchased 248,036 shares from 18 to 24 November 2016 at an average price of €57.14.

DSM Managing Board change

DSM announces the departure of Managing Board and Executive Committee member Stephan B. Tanda as of 1 February 2017.

DSM - repurchase of shares (11-17 November 2016)

DSM repurchased 360,149 shares from 11 to 17 November 2016 at an average price of €56.21.

DSM reports Q3 2016 results

DSM reports another strong quarter in Q3 2016.

DSM - repurchase of shares (4-10 November 2016)

DSM repurchased 514,484 shares from 4 to 10 November 2016 at an average price of €56.17.

DSM announces repurchase of shares to cover existing option plans

DSM intends to repurchase up to 1,700,000 ordinary shares in order to cover its commitments under management and personnel option plans.

DSM issues long-term €750 million bond

DSM announces the successful launch of a €750 million bond, with a ten-year maturity due in 2026, at a coupon of 0.75%.

DSM named leader in Dow Jones Sustainability World Index

DSM has been named the worldwide leader in the Materials industry group in the Dow Jones Sustainability World Index 2016.

DSM reports Q2 2016 results

DSM reports a second consecutive strong quarter in 2016.

DSM successfully completes secondary offering of shares in Patheon N.V.

DSM announces the successful completion of its secondary offering of 4,761,905 ordinary shares in Patheon N.V. in connection with Patheon N.V.’s Initial Public Offering of ordinary shares.

DSM finalizes repurchase of shares to cover existing option plans and stock dividend

DSM repurchased 83,073 shares from 15 to 21 July 2016 at an average price of €56.75 and concluded the program to repurchase 3,500,000 shares.

DSM informs market of final pricing of Patheon N.V. IPO

Patheon N.V., a company in which DSM holds approximately 53.5 million ordinary shares, has priced its Initial Public Offering at USD 21.00 per ordinary share.

DSM - repurchase of shares (8-14 July 2016)

DSM repurchased 107,432 shares from 8 to 14 July 2016 at an average price of €54.67.

DSM informs market of amended S-1 filing by Patheon N.V.

Patheon N.V., a company in which DSM holds approximately 53.5 million ordinary shares, has today commenced an Initial Public Offering.

DSM - repurchase of shares (1-7 July 2016)

DSM repurchased 95,055 shares from 1 to 7 July 2016 at an average price of €52.09.

DSM - repurchase of shares (24-30 June 2016)

DSM repurchased 248,553 shares from 24 to 30 June 2016 at an average price of €50.64.

DSM - repurchase of shares (17-23 June 2016)

DSM repurchased 115,202 shares from 17 to 23 June 2016 at an average price of €53.57.

DSM - repurchase of shares (10-16 June 2016)

DSM repurchased 125,684 shares from 10 to 16 June 2016 at an average price of €53.20.

DSM announces amendment to share repurchase program and reports repurchase of shares (3-9 June 2016)

DSM intends to increase the running share repurchase program by an additional 300,000 shares to a total of 3,500,000 to cover the interim stock dividend 2016.

DSM - repurchase of shares (27 May 2016 - 2 June 2016)

DSM repurchased 151,361 shares from 27 May to 2 June 2016 at an average price of €54.46.

DSM - repurchase of shares (20-26 May 2016)

DSM repurchased 152,420 shares from 20 to 26 May 2016 at an average price of €53.26

DSM - repurchase of shares (13-19 May 2016)

DSM repurchased 152,511 shares from 13 to 19 May 2016 at an average price of €52.54.

DSM - repurchase of shares (6-12 May 2016)

DSM repurchased 153,360 shares from 6 to 12 May 2016 at an average price of €52.27.

DSM - repurchase of shares (29 April - 5 May 2016)

DSM repurchased 153,694 shares from 29 April to 5 May 2016 at an average price of €52.34.

DSM provides update on Nutrition organization to support growth

DSM provides an update on the development of its Nutrition organization and several key positions to further support its growth plans.

DSM announces results of 2016 Annual General Meeting of Shareholders

DSM held its Annual General Meeting of Shareholders on 29 April 2016. Shareholders approved all resolutions on the agenda.

DSM - repurchase of shares (22-28 April 2016)

DSM repurchased 163,523 shares from 22 to 28 April 2016 at an average price of €53.25.

Final dividend 2015 Royal DSM

DSM declares a dividend for the financial year 2015 of €1.65 per ordinary share of €1.50 nominal value.

DSM reports Q1 2016 results

DSM reports a strong first quarter in 2016.

DSM - repurchase of shares (15-21 April 2016)

DSM repurchased 153,579 shares from 15 to 21 April 2016 at an average price of €52.05.

DSM - repurchase of shares (8-14 April 2016)

DSM repurchased 153,992 shares from 8 to 14 April 2016 at an average price of €50.01.

DSM - repurchase of shares (1-7 April 2016)

DSM repurchased 167,229 shares from 1 to 7 April 2016 at an average price of €47.8951.

DSM - repurchase of shares (29-31 March 2016)

DSM repurchased 93,033 shares from 29 to 31 March 2016 at an average price of €48.5712.

DSM Executive Committee members purchase DSM shares

All members of the Executive Committee purchase ordinary shares in Royal DSM, expressing their confidence in the growth prospects of the company.

DSM - repurchase of shares (18-24 March 2016)

DSM repurchased 159,637 shares from 18 to 24 March 2016 at an average price of €48.28.

DSM - repurchase of shares (11-17 March 2016)

DSM repurchased 161,667 shares from 11 to 17 March 2016 at an average price of €48.06.

DSM - repurchase of shares (4-10 March 2016)

DSM repurchased 232,331 shares from 4 to 10 March 2016 at an average price of €47.13.

DSM - repurchase of shares (26 February 2016 - 3 March 2016)

DSM repurchased 269,930 shares from 26 February to 3 March 2016 at an average price of €45.84.

DSM publishes 2015 Integrated Annual Report

DSM announces the publication of its 2015 Integrated Annual Report.

DSM - repurchase of shares (22-25 February 2016)

DSM repurchased 267,680 shares from 22 to 25 February 2016 at an average price of €43.94.

DSM welcomes new Sustainability Advisory Board member Ndidi Okonkwo Nwuneli

Ndidi Okonkwo Nwuneli, founder of LEAP Africa and co-founder of AACE Food Processing & Distribution Ltd and partner at Sahel Capital, an advisory and private equity firm, has joined DSM's Sustainability Advisory Board.

DSM announces repurchase of shares to cover existing option plans and stock dividend

DSM to repurchase 3,200,000 ordinary shares to cover commitments under management and personnel option plans and as part of the final dividend 2015.

DSM reports Q4 2015 results

Q4 Group net sales up 6% to €1,926m and EBITDA up 3% to €261m.

DSM proposes Pradeep Pant as new Supervisory Board member

At the Annual General Meeting of Shareholders the Supervisory Board will nominate Mr. Pradeep Pant for appointment as a member of DSM's Supervisory Board.

DSM and Syngenta to develop and commercialize biological solutions for agriculture

DSM and Syngenta R&D partnership to develop microbial-based agricultural solutions, including bio-controls, bio-pesticides and bio-stimulants.

DSM sets Strategy 2018

After a period of transformation, DSM will focus on improving its financial results through organic growth, reducing costs and strict capital allocation.

DSM reports Q3 2015 results

Sales up 8%, driven by 7% organic growth in Nutrition and foreign exchange.

DSM wins FD-Sijthoff prize for best annual report by a Dutch listed company

DSM awarded FD-Henri Sijthoff prize for the best annual report by a company listed on the AEX stock exchange in the Netherlands for its 2014 Integrated Annual Report.

DSM issues long-term €500 million bond

DSM successfully issued a €500 million 1.375% bond due 2022.

DSM among leaders in Dow Jones Sustainability World Index

DSM named among the worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index 2015.

DSM adjusts organizational model

Adjustments to organizational and operating model aim to create more agile, focused and cost efficient organization, with a stronger business and market focus and globally leveraged support functions.

DSM reports Q2 2015 results

Solid sales performance with a 12% increase to €1,965 million, supported by foreign exchange rates and 3% volume growth.

DSM and CVC finalize partnership for Polymer Intermediates and Composite Resins

Partnership finalized for DSM’s activities in Polymer Intermediates (Caprolactam & Acrylonitrile) and Composite Resins with formation of ChemicaInvest B.V..

DSM finalizes repurchase of shares to cover existing option plans

DSM repurchased 204,254 shares from 24 to 28 July 2015 at an average price of €52.44 and concluded the program to repurchase 2,300,000 shares.

DSM - repurchase of shares (17-23 July 2015)

DSM repurchased 184,648 shares from 17 to 23 July 2015 at an average price of €54.52.

DSM - repurchase of shares (10-16 July 2015)

DSM repurchased 74,088 shares from 10 to 16 July 2015 at an average price of €53.54.

DSM - repurchase of shares (3-9 July 2015)

DSM repurchased 190,870 shares from 3 to 9 July 2015 at an average price of €51.34.

DSM - repurchase of shares (26 June - 2 July 2015)

DSM repurchased 362,143 shares from 26 June to 2 July 2015 at an average price of €53.03.

DSM - repurchase of shares (19-25 June 2015)

DSM repurchased 245,123 shares from 19 to 25 June 2015 at an average price of €53.87.

DSM - repurchase of shares (12-18 June 2015)

DSM repurchased 223,561 shares from 12 to 18 June 2015 at an average price of €52.87.

DSM - repurchase of shares (5-11 June 2015)

DSM repurchased 185,315 shares from 5 to 11 June 2015 at an average price of €53.36.

DSM - repurchase of shares (29 May - 4 June 2015)

DSM repurchased 277,686 shares from 29 May to 4 June 2015 at an average price of €53.95.

DSM - repurchase of shares (22-28 May 2015)

DSM repurchased 128,219 shares from 22 to 28 May 2015 at an average price of €53.8102.

DSM - repurchase of shares (18-21 May 2015)

DSM repurchased 224,093 shares from 18 to 21 May 2015 at an average price of €53.18.

DSM announces repurchase of shares to cover existing option plans

DSM intends repurchasing 2,300,000 ordinary shares in order to cover its commitments under management and personnel option plans.

Final dividend 2014 Royal DSM

DSM declares dividend for the financial year 2014 of €1.65 per ordinary share.

DSM announces results of 2015 Annual General Meeting of Shareholders

DSM held its Annual General Meeting of Shareholders on 30 April 2015. Shareholders approved all resolutions on the agenda.

DSM reports Q1 2015 results

Sales of €1,886 million, up 11%, including 2% organic sales growth.

DSM finalizes sale of DSM Synres to Standard Investment

DSM Synres produced solvent-borne alkyd and acrylic coating resins for the global coatings, adhesives and graphic arts markets.

DSM provides 2014 comparative figures

Figures reflect reclassification of Polymer Intermediates cluster and DSM Composite Resins to discontinued operations. Corporate Activities are restated and also reflect the sale of DSM Synres.

DSM issues long-term €500 million bond

DSM has successfully issued a €500 million 1.0% bond due 2025.

DSM finalizes acquisition of Aland (China)

DSM finalizes acquisition of Aland, a Hong Kong-based company producing vitamin C in mainland China.

DSM Managing Board re-appointments

DSM proposes re-appointment of Stephan B. Tanda and announces departure of Stefan Doboczky as of 1 June 2015.

DSM and CVC announce partnership for Polymer Intermediates and Composite Resins

Partnership for DSM’s activities in Polymer Intermediates (Caprolactam and Acrylonitrile) and Composite Resins with formation of new company 65% owned by CVC and 35% by DSM.

DSM finalizes sale of Euroresins to Cathay Investments

Euroresins, a distributor of products to the composite resins industry, sold to Cathay Investments.

DSM publishes 2014 Integrated Annual Report

DSM announces publication of 2014 Integrated Annual Report.

DSM reports 2014 results

Sales of €9,181 million, a 4% increase versus 2013. In line with market expectations, DSM reported EBITDA of €1,168 million compared to €1,261 million in 2013.

DSM to sell Euroresins to Cathay Investments

DSM has reached agreement with Cathay Investments for the sale of Euroresins and the transaction is expected to close in Q1 2015.

DSM to sell DSM Synres to Standard Investment

DSM has reached agreement with Standard Investment for the sale of DSM Synres and the transaction is expected to close in Q1 2015.

DSM updates financial markets at its Capital Markets Day

DSM provides investors with update on its strategic progress and current priorities at annual Capital Markets Day.

DSM reports Q3 2014 results

Third quarter 2014 EBITDA from continuing operations of €315 million compared to €293 million in Q2 2014 and €331 million in Q3 2013.

DSM once again among leaders in DJ Sustainability World Index

DSM named among the worldwide leaders in the Materials industry group in the Dow Jones Sustainability World Index 2014.

First commercial-scale cellulosic ethanol plant in the U.S. opens for business

POET-DSM Advanced Biofuels proves its revolutionary technology that converts agricultural residue into renewable fuel at opening of its first commercial cellulosic ethanol plant.

DSM reports Q2 2014 results

DSM's second quarter 2014 EBITDA from continuing operations of €293 million compared to €332 million in Q2 2013, and €272 million in Q1 2014.

DSM to acquire Aland (China) to strengthen vitamin C position

DSM reaches agreement to acquire Aland, a Hong Kong-based company producing vitamin C in mainland China.

DSM reports fire in utilities building in Sisseln (CH)

Production of a few intermediates, mainly for Animal Nutrition & Health interrupted. Impact on customers expected to be minimal.

DSM finalizes repurchase of shares to cover existing option plans

DSM repurchased 69,522 shares from 16 to 19 May 2014 at an average price of €51.67 and concluded the program to repurchase 5,000,000 shares.

DSM - repurchase of shares (9-15 May 2014)

DSM repurchased 176,832 shares from 9 to 15 May 2014 at an average price of €51.97.

DSM - repurchase of shares (2-8 May 2014)

DSM repurchased 294,921 shares from 2 to 8 May 2014 at an average price of €52.03.

Final dividend 2013 Royal DSM

DSM declares dividend for the financial year 2013 of €1.65 per ordinary share.

DSM announces results of 2014 Annual General Meeting of Shareholders

DSM held its Annual General Meeting of Shareholders on 7 May 2014. Shareholders approved all resolutions on the agenda.

DSM reports Q1 2014 results

DSM reports first quarter EBITDA from continuing operations of €272 million compared to €301 million in Q1 2013.

DSM - repurchase of shares (25-30 April 2014)

DSM repurchased 201,426 shares from 25 to 30 April 2014 at an average price of €51.49.

DSM - repurchase of shares (22-24 April 2014)

DSM repurchased 170,120 shares from 22 to 24 April 2014 at an average price of €50.42.

DSM - repurchase of shares (11-17 April 2014)

DSM repurchased 231,586 shares from 11 to 17 April 2014 at an average price of €49.15.

DSM - repurchase of shares (4-10 April 2014)

DSM repurchased 256,801 shares from 4 to 10 April 2014 at an average price of €50.17.

DSM in exclusive discussions to acquire Aland (China)

DSM in exclusive discussions with Aland that may or may not result in the acquisition of this China-based global producer of vitamin C.

DSM - repurchase of shares (28 March - 3 April 2014)

DSM repurchased 149,321 shares from 28 March to 3 April 2014 at an average price of €50.05.

DSM - repurchase of shares (21-27 March 2014)

DSM repurchased 157,579 shares from 21 to 27 March 2014 at an average price of €48.46.

DSM - repurchase of shares (14-20 March 2014)

DSM repurchased 108,500 shares from 14 to 20 March 2014 at an average price of €46.51.

DSM - repurchase of shares (7-13 March 2014)

DSM repurchased 254,756 shares from 7 to 13 March 2014 at an average price of €47.40.

Royal DSM and JLL Partners Create DPx

USD 2.65 billion transaction to create global CDMO leader successfully completed.

DSM proposes appointment of new Chief Financial Officer

DSM to appoint Geraldine Matchett as Member of the Managing Board of Directors as of 1 August 2014 and as of 1 December 2014, she will become Chief Financial Officer.

DSM - repurchase of shares (27 February - 6 March 2014)

DSM repurchased 428,636 shares from 27 February to 6 March 2014 at an average price of €46.54.

DSM issues long-term €500 million bond

DSM issues €500 million 2.375% bond due 2024.

DSM resumes repurchase of shares to cover existing option plans

DSM intends to repurchase of 2,500,000 ordinary shares to cover commitments under management and personnel option plans.

DSM reports final 2013 results, increases dividend

For full year 2013 DSM delivered 18% higher EBITDA while facing challenging economic environment. In Q4 the company realized 30% higher EBITDA.

DSM finalizes repurchase of shares to cover existing option plans

DSM repurchased 874,725 shares from 17 January 2014 up to and including 21 January 2014 at an average price of €51.85 and concludes first part of program to repurchase 4-5 million shares in total.

DSM reports preliminary 2013 results, provides 2014 outlook

DSM delivered roughly 20% higher EBITDA for the full year 2013, in spite of the challenging economic environment and in Q4 realized an approximately 30% higher EBITDA.

DSM - repurchase of shares (10-16 January 2014)

DSM repurchased 245,742 shares from 10 to 16 January 2014 at an average price of €56.90.

DSM - repurchase of shares (6-9 January 2014)

DSM repurchased 112,588 shares from 6 to 9 January 2014 at an average price of €57.88.

DSM - repurchase of shares (13-19 December 2013)

DSM repurchased 154,586 shares from 13 to 19 December 2013 at an average price of €55.35.

DSM announces final terms of €300 million bond

Final Terms of the €300,000,000 1.75% Notes due 13 November 2019 adjusted to reflect investors have a put option in the event of a change of control.

DSM - repurchase of shares (6-12 December 2013)

DSM repurchased 185,761 shares from 6 to 12 December 2013 at an average price of €56.08.

DSM - repurchase of shares (29 November - 5 December 2013)

DSM repurchased 164,545 shares from 29 November to 5 December 2013 at an average price of €57.17.

DSM - repurchase of shares (22-28 November 2013)

DSM repurchased 198,288 shares from 22 to 28 November 2013 at an average price of €58.39.

DSM - repurchase of shares (15-21 November 2013)

DSM repurchased 346.038 shares from 15 to 21 November 2013 at an average price of €59.06.

Royal DSM and JLL create leading pharma services company in USD 2.6 bn transaction

Global CDMO company combines DSM Pharmaceutical Products and Patheon.

DSM - repurchase of shares (6-14 November 2013)

DSM repurchased 217,727 shares from 6 to 14 November 2013 at an average price of €58.05.

DSM issues long-term €300 mln bond

DSM successfully issues €300 million 1.75% bond due 2019.

DSM announces repurchase of shares to cover existing option plans

DSM intends to repurchase 2,500,000 ordinary shares to cover commitments under management and personnel option plans.

DSM maintains positive momentum in challenging markets

Q3 EBITDA of €342 million compared to €270 million in Q3 2012. 27% improvement realized despite ongoing challenging macro-economic environment.

DSM completes acquisition of stake in Andre Pectin (China)

DSM acquires 19% equity interest in Yantai Andre Pectin Co. Ltd., a China based producer of texturing ingredients.

DSM updates financial markets at its Capital Markets Day

DSM providing review of strategic progress and update on its 2015 targets at its annual Capital Markets Day.

DSM once again among leaders in DJ Sustainability World Index

DSM once again amongst leaders in chemical industry sector in Dow Jones Sustainability World Index 2013.

DSM delivers higher profits; full year outlook unchanged

DSM reports second quarter EBITDA of €345 million compared to €290 million in Q2 2012 and €311 million in Q1 2013.

DSM to better serve Nutrition customers in Asia with acquisition of Unitech (NZ)

DSM acquires Unitech Industries Limited, a New Zealand based producer of nutritional products for both human and animal markets.

DSM to acquire 19% interest in Andre Pectin (China)

Agreement to acquire 19% equity interest in Yantai Andre Pectin Co. Ltd. (Andre Pectin), a China based producer of texturing ingredients.

Final dividend 2012 Royal DSM

DSM declares a dividend for the financial year 2012 of €1.50 per ordinary share of €1.50 nominal value.

DSM announces results of 2013 Annual General Meeting of Shareholders

DSM held its Annual General Meeting of Shareholders on 3 May 2013. Shareholders approved all resolutions on the agenda.

DSM reports good start to the year in challenging environment

DSM reports first quarter EBITDA of €311 million compared to €306 million in Q1 2012 and €243 million in Q4 2012.

DSM and Rostekhnologii to cooperate on biotechnology and functional materials

Strategic partnership with Rostekhnologii (Rostec) in fields of biotechnology and functional materials.

DSM and Republic of Tatarstan sign MOU for fortified nutrition

Partnership with Ministry of Health Care of the Republic of Tatarstan aims to modernize the Republic’s public health sector through fortified nutrition.

DSM completes acquisition of Tortuga

DSM acquires Tortuga, a nutritional supplements company with a focus on pasture raised beef and dairy cattle for a total enterprise value of about €440 million.

DSM - proposed appointment to the Managing Board of Directors

DSM proposes appointing Mr. Dimitri de Vreeze to the Managing Board effective 1 September 2013.

DSM completes sale of participation in DEXPlastomers JV to Borealis

DSM sells its participation in DEXPlastomers, a 50/50 Joint Venture of DSM with affiliate of ExxonMobil Chemical, to Borealis.

DSM is positioned for strong EBITDA growth and increases dividend

DSM delivered growth across all clusters in 2012 excluding caprolactam. Nutrition represents more than 70% of total EBITDA and become high value, global business with attractive growth prospects across the full value chain.

DSM completes acquisition of Fortitech and strengthens its human nutrition business

Completing acquisition of Fortitech is another milestone in implementation of DSM’s Nutrition strategy.

DSM completes acquisition of Cargill’s cultures and enzymes business

Acquisition enables DSM to become a global tier one dairy ingredients supplier.

DSM awarded for its integrated reporting

DSM receives three prestigious awards in the Netherlands for its 2011 Integrated Annual Report.

DSM to sell participation in DEXPlastomers JV to Borealis

Agreement with Borealis AG reached for sale of DEXPlastomers V.o.F and DSM's LldPE Compact Solution Technology.

DSM to acquire Fortitech to strengthen human nutrition business

Definitive agreement to acquire Fortitech, Inc. (Fortitech) in an all cash transaction for a total enterprise value of $634 million.

DSM reports solid Q3 results despite weak economic conditions

DSM continues to generate good results mainly driven by Nutrition cluster and make good progress towards strategic goals with purchase of Tortuga and Cargill’s cultures and enzymes business.

DSM to acquire Cargill’s cultures and enzymes business

DSM to acquire Cargill’s cultures and enzymes business in an all cash transaction for a total enterprise value of €85 million.

DSM updates market on strategy progress at Capital Markets Days

DSM updates financial community at its annual Capital Markets Days on progress made with its DSM in Motion: driving focused growth strategy.

DSM appoints new President DSM Nutritional Products

Chris Goppelsroeder appointed President and CEO DSM Nutritional Products effective 1 January 2013.

DSM in exclusive discussions to acquire Cargill’s cultures and enzymes business

DSM in exclusive discussions with Cargill which may, or may not result in DSM's acquisition of Cargill’s cultures and enzymes business.

DSM amongst leaders in Dow Jones Sustainability World Index

DSM again among leaders in chemical industry sector in the Dow Jones Sustainability World Index 2012.

DSM to acquire Tortuga to strengthen animal nutrition business

Definitive agreement to acquire Tortuga Companhia Zootécnica Agrária (Tortuga) in all cash transaction for total enterprise value of about €465 million.

DSM reports robust Q2 in challenging environment

Life Sciences cluster accounts for around 70% of Q2 EBITDA offsetting weakness caused by caprolactam in Materials Sciences. Other Materials Sciences businesses improve.

DSM completes acquisition of Ocean Nutrition Canada and expands its Nutritional Lipids growth platform

DSM acquires Ocean Nutrition Canada, leading global provider of fish-oil derived nutritional products to dietary supplement and food and beverage markets for a total enterprise value of C$540 million.

DSM completes acquisition of Kensey Nash and strengthens its biomedical business

DSM completes acquisition of Kensey Nash for a total enterprise value of approximately $360 million.

DSM tender offer for Kensey Nash is successful; acquisition expected to close within next few days

Tender offer to purchase all outstanding shares of common stock of Kensey Nash Corporation at a price of $38.50 per share successful.

DSM announces expiration of waiting period under Hart-Scott-Rodino Act

Expiration of mandatory waiting period under Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for previously announced tender offer for all outstanding shares of common stock of Kensey Nash Corporation.

DSM enzymes for cellulosic ethanol qualified by DONG Energy

DSM qualified as supplier of enzymes for DONG Energy - Inbicon’s wheat straw to cellulosic ethanol process.

DSM commences tender offer for Kensey Nash

DSM commences previously announced tender offer for all outstanding shares of common stock of Kensey Nash at a price of $38.50 per share.

DSM to acquire Ocean Nutrition Canada to expand its Nutritional Lipids growth platform

Definitive agreement with Clearwater Fine Foods and funds managed by Richardson Capital to acquire Ocean Nutrition Canada for a total enterprise value of C$540 million.

DSM appoints two new Supervisory Board members

Annual General Meeting of Shareholders approves appointing Mrs. Victoria Haynes and Mrs. Eileen Kennedy as Supervisory Board members.

Final dividend 2011 Royal DSM

DSM declares a dividend for 2011 of €1.45 per ordinary share of €1.50 par value.

DSM announces results of 2012 Annual General Meeting of Shareholders

DSM held its Annual General Meeting of Shareholders on 11 May 2012. Shareholders approved all resolutions on the agenda.

DSM reports positive start to the year with robust Q1 results

In a challenging business environment, DSM continued to make good progress in Q1 and the robust results represent a positive start to 2012.

DSM agrees to acquire Kensey Nash to strengthen its biomedical business

DSM will acquire all outstanding shares of common stock of Kensey Nash through a cash tender offer, followed by a merger with a subsidiary of DSM, for $38.50 in cash per share for total enterprise value of approximately $360 million.

DSM announces management changes

Jos Op Heij new Senior Vice President Corporate Control and Accounting, Hans Vossen new VP Corporate Treasury & Dave Huizing new VP Investor Relations.

DSM acquires food enzymes business and key technology from Verenium

DSM acquires certain assets, licenses and other agreements in the area of food enzymes and oilseed processing from Verenium for a total consideration including transaction and related expenses of $37 million.

DSM reports another strong year and increases dividend

2011 was another strong year for DSM despite challenges of global economy, adverse currency movements and high raw material costs and increases dividend for second consecutive year.

DSM appoints new General Counsel

Cees Los joins DSM as General Counsel and Director Legal Affairs as of 15 April 2012.

DSM and POET to make advanced biofuels a reality by 2013

Joint Venture to commercially demonstrate and license cellulosic bio-ethanol, the next step in the development of biofuels, based on their proprietary and complementary technologies.